Use the keywords feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#1
REVIEW
G Pernod, P Albaladejo, A Godier, C M Samama, S Susen, Y Gruel, N Blais, P Fontana, A Cohen, J V Llau, N Rosencher, J F Schved, E de Maistre, M M Samama, P Mismetti, P Sié
New direct oral anticoagulants (NOAC), inhibitors of factor IIa or Xa, are expected to be widely used for the treatment of venous thromboembolic disease, or in case of atrial fibrillation. Such anticoagulant treatments are known to be associated with haemorrhagic complications. Moreover, it is likely that such patients on long-term treatment with NOAC will be exposed to emergency surgery or invasive procedures. Due to the present lack of experience in such conditions, we cannot make recommendations, but only propose management for optimal safety as regards the risk of bleeding in such emergency conditions...
October 2013: Annales Françaises D'anesthèsie et de Rèanimation
1
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
